Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 1.252
Filter
1.
Medicine (Baltimore) ; 103(27): e38846, 2024 Jul 05.
Article in English | MEDLINE | ID: mdl-38968451

ABSTRACT

The field of regenerative medicine for sports injuries has grown significantly in the 21st century. This study attempted to provide an overview of the current state of research and key findings regarding the relationship between sport and regenerative medicine in general, identifying trends and hotspots in research topics. We gathered the literature from the Web of Science (WOS) database covering the last 10 years (2013-2023) pertaining to regenerative medicine for sporter and applied Citespace to assess the knowledge mapping. The findings demonstrated that there were 572, with a faster increase after 2018. The country, institution, and author with the most publications are the USA, Harvard University, and Maffulli Nicola. In addition, the most co-cited reference is J Acad Nutr Diet (2016) (199). Adipose tissue, high tibial osteotomy, and bone marrow are the hot spots in this field in the next few years.


Subject(s)
Bibliometrics , Regenerative Medicine , Regenerative Medicine/methods , Regenerative Medicine/trends , Humans , Sports Medicine/trends , Sports Medicine/methods , Biomedical Research/trends , Athletic Injuries/therapy
2.
Croat Med J ; 65(3): 268-287, 2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38868973

ABSTRACT

This review evaluates the current landscape and future directions of regenerative medicine for knee cartilage repair, with a particular focus on tissue engineering strategies. In this context, scaffold-based approaches have emerged as promising solutions for cartilage regeneration. Synthetic scaffolds, while offering superior mechanical properties, often lack the biological cues necessary for effective tissue integration. Natural scaffolds, though biocompatible and biodegradable, frequently suffer from inadequate mechanical strength. Hybrid scaffolds, combining elements of both synthetic and natural materials, present a balanced approach, enhancing both mechanical support and biological functionality. Advances in decellularized extracellular matrix scaffolds have shown potential in promoting cell infiltration and integration with native tissues. Additionally, bioprinting technologies have enabled the creation of complex, bioactive scaffolds that closely mimic the zonal organization of native cartilage, providing an optimal environment for cell growth and differentiation. The review also explores the potential of gene therapy and gene editing techniques, including CRISPR-Cas9, to enhance cartilage repair by targeting specific genetic pathways involved in tissue regeneration. The integration of these advanced therapies with tissue engineering approaches holds promise for developing personalized and durable treatments for knee cartilage injuries and osteoarthritis. In conclusion, this review underscores the importance of continued multidisciplinary collaboration to advance these innovative therapies from bench to bedside and improve outcomes for patients with knee cartilage damage.


Subject(s)
Cartilage, Articular , Regenerative Medicine , Tissue Engineering , Tissue Scaffolds , Humans , Tissue Engineering/methods , Regenerative Medicine/trends , Regenerative Medicine/methods , Cartilage, Articular/injuries , Cartilage, Articular/physiology , Knee Injuries/therapy , Knee Injuries/surgery , Genetic Therapy/trends , Genetic Therapy/methods , Regeneration
3.
Mil Med Res ; 11(1): 31, 2024 May 27.
Article in English | MEDLINE | ID: mdl-38797843

ABSTRACT

Aging and regeneration represent complex biological phenomena that have long captivated the scientific community. To fully comprehend these processes, it is essential to investigate molecular dynamics through a lens that encompasses both spatial and temporal dimensions. Conventional omics methodologies, such as genomics and transcriptomics, have been instrumental in identifying critical molecular facets of aging and regeneration. However, these methods are somewhat limited, constrained by their spatial resolution and their lack of capacity to dynamically represent tissue alterations. The advent of emerging spatiotemporal multi-omics approaches, encompassing transcriptomics, proteomics, metabolomics, and epigenomics, furnishes comprehensive insights into these intricate molecular dynamics. These sophisticated techniques facilitate accurate delineation of molecular patterns across an array of cells, tissues, and organs, thereby offering an in-depth understanding of the fundamental mechanisms at play. This review meticulously examines the significance of spatiotemporal multi-omics in the realms of aging and regeneration research. It underscores how these methodologies augment our comprehension of molecular dynamics, cellular interactions, and signaling pathways. Initially, the review delineates the foundational principles underpinning these methods, followed by an evaluation of their recent applications within the field. The review ultimately concludes by addressing the prevailing challenges and projecting future advancements in the field. Indubitably, spatiotemporal multi-omics are instrumental in deciphering the complexities inherent in aging and regeneration, thus charting a course toward potential therapeutic innovations.


Subject(s)
Aging , Genomics , Proteomics , Regenerative Medicine , Aging/physiology , Humans , Regenerative Medicine/methods , Regenerative Medicine/trends , Genomics/methods , Proteomics/methods , Metabolomics/methods , Epigenomics/methods , Multiomics
4.
Mo Med ; 121(2): 170-176, 2024.
Article in English | MEDLINE | ID: mdl-38694604

ABSTRACT

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) has emerged as a powerful gene editing technology that is revolutionizing biomedical research and clinical medicine. The CRISPR system allows scientists to rewrite the genetic code in virtually any organism. This review provides a comprehensive overview of CRISPR and its clinical applications. We first introduce the CRISPR system and explain how it works as a gene editing tool. We then highlight current and potential clinical uses of CRISPR in areas such as genetic disorders, infectious diseases, cancer, and regenerative medicine. Challenges that need to be addressed for the successful translation of CRISPR to the clinic are also discussed. Overall, CRISPR holds great promise to advance precision medicine, but ongoing research is still required to optimize delivery, efficacy, and safety.


Subject(s)
CRISPR-Cas Systems , Gene Editing , Humans , Gene Editing/methods , Neoplasms/genetics , Neoplasms/therapy , Genetic Therapy/methods , Genetic Therapy/trends , Clustered Regularly Interspaced Short Palindromic Repeats , Regenerative Medicine/methods , Regenerative Medicine/trends , Precision Medicine/methods , Precision Medicine/trends
5.
Hum Cell ; 37(4): 904-916, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38743204

ABSTRACT

Mesenchymal stem/stromal cells (MSCs), originating from the mesoderm, represent a multifunctional stem cell population capable of differentiating into diverse cell types and exhibiting a wide range of biological functions. Despite more than half a century of research, MSCs continue to be among the most extensively studied cell types in clinical research projects globally. However, their significant heterogeneity and phenotypic instability have significantly hindered their exploration and application. Single-cell sequencing technology emerges as a powerful tool to address these challenges, offering precise dissection of complex cellular samples. It uncovers the genetic structure and gene expression status of individual contained cells on a massive scale and reveals the heterogeneity among these cells. It links the molecular characteristics of MSCs with their clinical applications, contributing to the advancement of regenerative medicine. With the development and cost reduction of single-cell analysis techniques, sequencing technology is now widely applied in fundamental research and clinical trials. This study aimed to review the application of single-cell sequencing in MSC research and assess its prospects.


Subject(s)
Mesenchymal Stem Cells , Regenerative Medicine , Single-Cell Analysis , Single-Cell Analysis/methods , Single-Cell Analysis/trends , Humans , Mesenchymal Stem Cells/cytology , Regenerative Medicine/methods , Regenerative Medicine/trends , Cell Differentiation/genetics , Gene Expression/genetics
6.
Article in Chinese | MEDLINE | ID: mdl-38664023

ABSTRACT

Wound regeneration and repair is one of the primary research fields in burn and wound repair surgery. In recent years, with the continuous advancement of treatment concept and technologies in the field of rehabilitation, the connection between rehabilitation treatment and wound regeneration and repair has become closer, forming a new concept "regenerative rehabilitation". This article discussed the concept formation and development status of regenerative rehabilitation, and the future development and potential leading value of regenerative rehabilitation field.


Subject(s)
Regeneration , Wound Healing , Humans , Regeneration/physiology , Burns/rehabilitation , Regenerative Medicine/methods , Regenerative Medicine/trends
7.
J Tissue Viability ; 33(2): 332-344, 2024 May.
Article in English | MEDLINE | ID: mdl-38594147

ABSTRACT

Mesenchymal stem cell-derived exosomes (MSCs-EXO) have received a lot of interest recently as a potential therapeutic tool in regenerative medicine. Extracellular vesicles (EVs) known as exosomes (EXOs) are crucial for cell-cell communication throughout a variety of activities including stress response, aging, angiogenesis, and cell differentiation. Exploration of the potential use of EXOs as essential therapeutic effectors of MSCs to encourage tissue regeneration was motivated by success in the field of regenerative medicine. EXOs have been administered to target tissues using a variety of methods, including direct, intravenous, intraperitoneal injection, oral delivery, and hydrogel-based encapsulation, in various disease models. Despite the significant advances in EXO therapy, various methods are still being researched to optimize the therapeutic applications of these nanoparticles, and it is not completely clear which approach to EXO administration will have the greatest effects. Here, we will review emerging developments in the applications of EXOs loaded into decellularized tissues as therapeutic agents for use in regenerative medicine in various tissues.


Subject(s)
Exosomes , Regenerative Medicine , Regenerative Medicine/methods , Regenerative Medicine/trends , Exosomes/physiology , Humans , Animals , Mesenchymal Stem Cells/physiology
8.
J Oral Biosci ; 66(2): 288-299, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38403241

ABSTRACT

BACKGROUND: Regenerative dentistry aims to enhance the structure and function of oral tissues and organs. Modern tissue engineering harnesses cell and gene-based therapies to advance traditional treatment approaches. Studies have demonstrated the potential of mesenchymal stem cells (MSCs) in regenerative dentistry, with some progressing to clinical trials. This review comprehensively examines animal studies that have utilized MSCs for various therapeutic applications. Additionally, it seeks to bridge the gap between related findings and the practical implementation of MSC therapies, offering insights into the challenges and translational aspects involved in transitioning from preclinical research to clinical applications. HIGHLIGHTS: To achieve this objective, we have focused on the protocols and achievements related to pulp-dentin, alveolar bone, and periodontal regeneration using dental-derived MSCs in both animal and clinical studies. Various types of MSCs, including dental-derived cells, bone-marrow stem cells, and umbilical cord stem cells, have been employed in root canals, periodontal defects, socket preservation, and sinus lift procedures. Results of such include significant hard tissue reconstruction, functional pulp regeneration, root elongation, periodontal ligament formation, and cementum deposition. However, cell-based treatments for tooth and periodontium regeneration are still in early stages. The increasing demand for stem cell therapies in personalized medicine underscores the need for scientists and responsible organizations to develop standardized treatment protocols that adhere to good manufacturing practices, ensuring high reproducibility, safety, and cost-efficiency. CONCLUSION: Cell therapy in regenerative dentistry represents a growing industry with substantial benefits and unique challenges as it strives to establish sustainable, long-term, and effective oral tissue regeneration solutions.


Subject(s)
Tissue Engineering , Humans , Animals , Tissue Engineering/methods , Regeneration/physiology , Regenerative Medicine/methods , Regenerative Medicine/trends , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cell Transplantation/methods , Dental Pulp/cytology , Dental Pulp/physiology , Dentistry/trends , Dentistry/methods
9.
Rev. clín. esp. (Ed. impr.) ; 223(10): 619-628, dic. 2023. ilus, graf
Article in Spanish | IBECS | ID: ibc-228440

ABSTRACT

Las células madre de origen mesenquimal (CMM) suscitan un interés especial debido a sus propiedades regenerativas, antiinflamatorias, antiapoptóticas, contra el estrés oxidativo, antitumorales o antimicrobianas. Sin embargo, su implementación en clínica se topa con inconvenientes de la terapia celular como la incompatibilidad inmunológica, la formación de tumores, la posible transmisión de infecciones, la entrada en senescencia celular y la difícil evaluación de seguridad, dosis y potencia; así como complejas condiciones de almacenamiento, elevado coste económico o uso clínico poco práctico. Considerando que los efectos positivos de las CMM se deben, en gran medida, a los efectos paracrinos mediados por el conjunto de sustancias que segregan (factores de crecimiento, citoquinas, quimiocinas o microvesículas), la obtención in vitro de esos productos biológicos posibilita una medicina regenerativa libre de células sin los inconvenientes de la terapia celular. No obstante, esa nueva innovación terapéutica implica retos, como el reconocimiento de la heterogeneidad biológica de las CMM y la optimización y estandarización de su secretoma (AU)


Stem cells of mesenchymal origin (MSC) arouse special interest due to their regenerative, anti-inflammatory, anti-apoptotic, anti-oxidative stress, antitumor or antimicrobial properties. However, its implementation in the clinic runs into drawbacks of cell therapy (immunological incompatibility, tumor formation, possible transmission of infections, entry into cellular senescence, difficult evaluation of safety, dose and potency; complex storage conditions, high economic cost or impractical clinical use). Considering that the positive effects of MSC are due, to a large extent, to the paracrine effects mediated by the set of substances they secrete (growth factors, cytokines, chemokines or microvesicles), the in vitro obtaining of these biological products makes possible a medicine cell-free regenerative therapy without the drawbacks of cell therapy. However, this new therapeutic innovation implies challenges, such as the recognition of the biological heterogeneity of MSC and the optimization and standardization of their secretome (AU)


Subject(s)
Humans , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cell Transplantation/trends , Regenerative Medicine/methods , Regenerative Medicine/trends
10.
Science ; 380(6647): 796-798, 2023 05 26.
Article in English | MEDLINE | ID: mdl-37228215

ABSTRACT

Bridging knowledge gaps could enable regenerative therapy.


Subject(s)
Regenerative Medicine , Regenerative Medicine/methods , Regenerative Medicine/trends , Humans
11.
J Cosmet Dermatol ; 22 Suppl 1: 1-7, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36988470

ABSTRACT

BACKGROUND: Regenerative aesthetics (RA) is an emerging subfield based on many of the principles of regenerative medicine (RM). In order to ensure that the development of regenerative aesthetics is based on accepted regenerative concepts and to optimize treatment strategies, it is important to establish clear definitions, fundamental aims and consider the impact of the predominant RA tissue environment RM focuses on the regeneration of injured or diseased tissue, while RA aims to restore youthful properties to aging, senescent tissue. The distinction is key in understanding how best to develop treatments for these different goals. AIMS AND METHODS: The current review suggests key concepts, definitions, and foundations of regenerative aesthetic approaches and examines current evidence supporting this. It considers the importance of the aging tissue environment, the essential regenerative goals of restored tissue structure and function and introduces the concept of regenerative scaffolds with a focus on CaHA. Current techniques in the field and promising future directions are also discussed. CONCLUSION: Regenerative aesthetics is an evolving subfield of regenerative medicine. Establishing clear definitions, identifying the challenges of the aging soft tissue environment and re-evaluating current evidence in light of regenerative goals are vital for the continuing evolution of this medical field.


Subject(s)
Aging , Regeneration , Regenerative Medicine , Humans , Aging/physiology , Regenerative Medicine/methods , Regenerative Medicine/trends , Tissue Engineering/methods , Tissue Engineering/trends , Esthetics , Regeneration/physiology , Tissue Scaffolds , Durapatite/therapeutic use
12.
Biochimie ; 207: 33-48, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36427681

ABSTRACT

Mesenchymal stem/stromal cells (MSCs) are multipotent somatic cells that have been widely explored in the field of regenerative medicine. MSCs possess the ability to secrete soluble factors as well as lipid bound extracellular vesicles (EVs). MSCs have gained increased interest and attention as a result of their therapeutic properties, which are thought to be attributed to their secretome. However, while the use of MSCs as whole cells pose heterogeneity concerns and survival issues post-transplantation, such limitations are absent in cell-free EV-based treatments. EVs derived from MSCs are promising therapeutic agents for a range of clinical conditions and disorders owing to their immunomodulatory, pro-regenerative, anti-inflammatory, and antifibrotic activity. Recent successes with preclinical studies using EVs for repair and regeneration of damaged tissues such as cardiac tissue, lung, liver, pancreas, bone, skin, cornea, and blood diseases are discussed in this review. We also discuss delivery strategies of EVs using biomaterials as delivery vehicles through systemic or local administration. Despite its effectiveness in preclinical investigations, the application of MSC-EV in clinical settings will necessitate careful consideration surrounding issues such as: i) scalability and isolation, ii) biodistribution, iii) targeting specific tissues, iv) quantification and characterization, and v) safety and efficacy of dosage. The future of EVs in regenerative medicine is promising yet still needs further investigation on enhancing the efficacy, scalability, and potency for clinical applications.


Subject(s)
Extracellular Vesicles , Mesoderm , Regeneration , Regenerative Medicine , Stem Cells , Extracellular Vesicles/classification , Extracellular Vesicles/immunology , Extracellular Vesicles/metabolism , Regenerative Medicine/methods , Regenerative Medicine/standards , Regenerative Medicine/trends , Mesoderm/cytology , Stem Cells/cytology , Humans , Animals , Biotechnology/methods , Biotechnology/standards , Biotechnology/trends
13.
Science ; 377(6610): eabm4443, 2022 09 02.
Article in English | MEDLINE | ID: mdl-36048959

ABSTRACT

Heart regenerative medicine has been gradually evolving from a view of the heart as a nonregenerative organ with terminally differentiated cardiac muscle cells. Understanding the biology of the heart during homeostasis and in response to injuries has led to the realization that cellular communication between all cardiac cell types holds great promise for treatments. Indeed, recent studies highlight new disease-reversion concepts in addition to cardiomyocyte renewal, such as matrix- and vascular-targeted therapies, and immunotherapy with a focus on inflammation and fibrosis. In this review, we will discuss the cross-talk within the cardiac microenvironment and how specific therapies aim to target the hostile cardiac milieu under pathological conditions.


Subject(s)
Heart Diseases , Myocytes, Cardiac , Regeneration , Regenerative Medicine , Animals , Cell Communication , Cell Differentiation , Heart Diseases/therapy , Humans , Mice , Myocytes, Cardiac/physiology , Regeneration/physiology , Regenerative Medicine/trends
14.
Dermatol Surg ; 48(1): 101-108, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34904577

ABSTRACT

BACKGROUND: Regenerative aesthetics is an emerging branch of regenerative medicine with therapies aimed at recapturing youthful structure and function using the body's own systems. OBJECTIVE: To introduce the field of regenerative aesthetics, and to explore themes and evidence surrounding current and emerging therapies in the field. MATERIALS AND METHODS: A review of the literature was performed for each of the 3 pillars of regeneration; namely, stem cells, biochemical cues, and scaffolds. RESULTS: Herein, we provide an overview of the field of regenerative aesthetics, a discussion surrounding the 3 pillars of regeneration, and an overview of the evidence supporting current and emerging therapeutic modalities that could play a pivotal role in the future of aesthetic treatments. CONCLUSION: An enhanced understanding of this field can serve to further enhance our awareness about the regenerative effects of therapies we already offer, in addition to providing inspiration for future innovation.


Subject(s)
Esthetics , Regenerative Medicine/methods , Rejuvenation , Humans , Regenerative Medicine/trends
15.
Eur J Pharmacol ; 918: 174657, 2022 Mar 05.
Article in English | MEDLINE | ID: mdl-34871557

ABSTRACT

Mesenchymal stem cells (MSCs) are adult stem cells owing to their regenerative potential and multilineage potency. MSCs have wide-scale applications either in their native cellular form or in conjugation with specific biomaterials as nanocomposites. Majorly, these natural or synthetic biomaterials are being used in the form of metallic and non-metallic nanoparticles (NPs) to encapsulate MSCs within hydrogels like alginate or chitosan or drug cargo loading into MSCs. In contrast, nanofibers of polymer scaffolds such as polycaprolactone (PCL), poly-lactic-co-glycolic acid (PLGA), poly-L-lactic acid (PLLA), silk fibroin, collagen, chitosan, alginate, hyaluronic acid (HA), and cellulose are used to support or grow MSCs directly on it. These MSCs based nanotherapies have application in multiple domains of biomedicine including wound healing, bone and cartilage engineering, cardiac disorders, and neurological disorders. This review focused on current approaches of MSCs-based therapies and has been divided into two major sections. The first section elaborates on MSC-based nano-therapies and their plausible applications including exosome engineering and NPs encapsulation. The following section focuses on the various MSC-based scaffold approaches in tissue engineering. Conclusively, current review mainly discussed the MSC-based nanocomposite's current approaches their advantages and limitations for building effective regenerative medicines.


Subject(s)
Mesenchymal Stem Cells/physiology , Nanoparticles/therapeutic use , Tissue Engineering/methods , Tissue Scaffolds , Biocompatible Materials/pharmacology , Humans , Regenerative Medicine/methods , Regenerative Medicine/trends
16.
S Afr Med J ; 111(11): 1055-1059, 2021 11 05.
Article in English | MEDLINE | ID: mdl-34949268

ABSTRACT

The discovery of human leucocyte antigen (HLA), serological matching and HLA-typing techniques, combined with the development of immunosuppressive medicines and improvements in infection control, have opened the way to cell, tissue and vascularised organ transplantation. Since the early 1960s, more than a million haematopoietic progenitor cell (HPC) transplantations have been performed worldwide to restore haematopoiesis and support immune system recovery after bone marrow ablation. HPC transplantation uses minimally manipulated autologous or allogeneic cells to restore the homologous functions of bone marrow. Research in biological sciences supported by new technologies is increasingly translated into therapeutic products intended to augment, repair, replace or regenerate genes, cells, tissues, organs and metabolic processes in the body. These products are referred to as regenerative medicine therapies or advanced therapy medicinal products, and include gene therapies, cell-based therapies and engineered tissue products.


Subject(s)
Regenerative Medicine/trends , Cell- and Tissue-Based Therapy/trends , Genetic Therapy/trends , Hematopoietic Stem Cell Transplantation , Histocompatibility Testing , Humans , South Africa , Tissue Engineering/trends
17.
Int J Mol Sci ; 22(24)2021 Dec 15.
Article in English | MEDLINE | ID: mdl-34948251

ABSTRACT

An approach called cell-free therapy has rapidly developed in regenerative medicine over the past decade. Understanding the molecular mechanisms and signaling pathways involved in the internal potential of tissue repair inspires the development of new strategies aimed at controlling and enhancing these processes during regeneration. The use of stem cell mobilization, or homing for regeneration based on endogenous healing mechanisms, prompted a new concept in regenerative medicine: endogenous regenerative medicine. The application of cell-free therapeutic agents leading to the recruitment/homing of endogenous stem cells has advantages in overcoming the limitations and risks associated with cell therapy. In this review, we discuss the potential of cell-free products such as the decellularized extracellular matrix, growth factors, extracellular vesicles and miRNAs in endogenous bone and dental regeneration.


Subject(s)
Guided Tissue Regeneration/trends , Regenerative Medicine/methods , Regenerative Medicine/trends , Animals , Bone Regeneration/physiology , Bone and Bones/physiology , Cell- and Tissue-Based Therapy/methods , Cell- and Tissue-Based Therapy/trends , Decellularized Extracellular Matrix/pharmacology , Extracellular Vesicles/physiology , Guided Tissue Regeneration/methods , Humans , Intercellular Signaling Peptides and Proteins/pharmacology , MicroRNAs/therapeutic use , Stem Cells , Tissue Engineering , Tooth/physiology , Wound Healing
18.
Int J Mol Sci ; 22(21)2021 Oct 23.
Article in English | MEDLINE | ID: mdl-34768869

ABSTRACT

For twenty-five years, attempts have been made to use MSCs in the treatment of various diseases due to their regenerative and immunomodulatory properties. However, the results are not satisfactory. Assuming that MSCs can be replaced in some therapies by the active factors they produce, the immortalized MSCs line was established from human adipose tissue (HATMSC1) to produce conditioned media and test its regenerative potential in vitro in terms of possible clinical application. The production of biologically active factors by primary MSCs was lower compared to the HATMSC1 cell line and several factors were produced only by the cell line. It has been shown that an HATMSC1-conditioned medium increases the proliferation of various cell types, augments the adhesion of cells and improves endothelial cell function. It was found that hypoxia during culture resulted in an augmentation in the pro-angiogenic factors production, such as VEGF, IL-8, Angiogenin and MCP-1. The immunomodulatory factors caused an increase in the production of GM-CSF, IL-5, IL-6, MCP-1, RANTES and IL-8. These data suggest that these factors, produced under different culture conditions, could be used for different medical conditions, such as in regenerative medicine, when an increased concentration of pro-angiogenic factors may be beneficial, or in inflammatory diseases with conditioned media with a high concentration of immunomodulatory factors.


Subject(s)
Cell Culture Techniques/methods , Culture Media, Conditioned/pharmacology , Mesenchymal Stem Cells/metabolism , Adipose Tissue/metabolism , Angiogenesis Inducing Agents/metabolism , Cell Differentiation , Cell Line , Cell Proliferation , Cells, Cultured , Culture Media, Conditioned/metabolism , Cytokines/metabolism , Endothelial Cells/metabolism , Humans , Immunomodulation , Immunotherapy , Neovascularization, Physiologic/physiology , Regenerative Medicine/methods , Regenerative Medicine/trends
19.
Int J Mol Sci ; 22(21)2021 Oct 26.
Article in English | MEDLINE | ID: mdl-34768969

ABSTRACT

Inherited retinal degenerations (IRDs) are a diverse group of conditions that are often characterized by the loss of photoreceptors and blindness. Recent innovations in molecular biology and genomics have allowed us to identify the causative defects behind these dystrophies and to design therapeutics that target specific mechanisms of retinal disease. Recently, the FDA approved the first in vivo gene therapy for one of these hereditary blinding conditions. Current clinical trials are exploring new therapies that could provide treatment for a growing number of retinal dystrophies. While the field has had early success with gene augmentation strategies for treating retinal disease based on loss-of-function mutations, many novel approaches hold the promise of offering therapies that span the full spectrum of causative mutations and mechanisms. Here, we provide a comprehensive review of the approaches currently in development including a discussion of retinal neuroprotection, gene therapies (gene augmentation, gene editing, RNA modification, optogenetics), and regenerative stem or precursor cell-based therapies. Our review focuses on technologies that are being developed for clinical translation or are in active clinical trials and discusses the advantages and limitations for each approach.


Subject(s)
Cell- and Tissue-Based Therapy/trends , Molecular Targeted Therapy/trends , Retinal Degeneration/genetics , Retinal Degeneration/therapy , Gene Editing/trends , Genetic Therapy/trends , Humans , Neuroprotection , Optogenetics/trends , Regenerative Medicine/trends
20.
J Am Coll Cardiol ; 78(21): 2092-2105, 2021 11 23.
Article in English | MEDLINE | ID: mdl-34794691

ABSTRACT

This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors' own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper's main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.


Subject(s)
Heart Failure/therapy , Myocardial Infarction/therapy , Regeneration/physiology , Regenerative Medicine/methods , Translational Research, Biomedical/methods , Ventricular Remodeling/physiology , Animals , Blood Vessel Prosthesis/trends , Cell- and Tissue-Based Therapy/methods , Cell- and Tissue-Based Therapy/trends , Heart Failure/physiopathology , Humans , Myocardial Infarction/physiopathology , Myocytes, Cardiac/physiology , Myocytes, Cardiac/transplantation , Regenerative Medicine/trends , Review Literature as Topic , Translational Research, Biomedical/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...